SERA SERA PROGNOSTICS, INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1534969 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY-2.6%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38,755.2%
Net margin-34,866.7%
FCF margin-30,199.0%
EBITDA margin-37,922.9%
Returns
ROE-49.7%
ROA-35.6%
ROIC (approx.)-46.5%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio1.88x
Interest coverage-5,315.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue508.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $81,000 | $77,000 |
| Cost of revenue | $164,000 | $82,000 |
| Gross profit | -$83,000 | -$5,000 |
| R&D expense | $13.17M | $14.73M |
| SG&A expense | $16.70M | $16.13M |
| Operating income | -$36.50M | -$36.63M |
| Interest expense | $9,000 | $28,000 |
| Pretax income | -$31.93M | -$32.90M |
| Income tax | $0 | $0 |
| Net income | -$31.93M | -$32.90M |
| EBITDA | -$35.56M | -$35.80M |
| EPS (basic) | -0.67 | -0.99 |
| EPS (diluted) | -0.67 | -0.99 |
| Weighted avg. shares (diluted) | 47.66M | 33.16M |
| Balance sheet | ||
| Cash & equivalents | $3.94M | $4.04M |
| Short-term investments | $35.26M | $42.19M |
| Receivables | $12,000 | $34,000 |
| Current assets | $40.77M | $47.60M |
| PP&E, net | $1.15M | $1.24M |
| Intangibles | $910,000 | $1.03M |
| Total assets | $101.93M | $72.58M |
| Current liabilities | $24.19M | $24.77M |
| Total liabilities | $26.52M | $24.77M |
| Shareholders' equity | $75.41M | $47.80M |
| Cash flow statement | ||
| Operating cash flow | -$25.62M | -$14.19M |
| Capital expenditure | $726,000 | $56,000 |
| Free cash flow | -$26.35M | -$14.24M |
| Investing cash flow | -$28.50M | $11.74M |
| Financing cash flow | $54.03M | $2.61M |
| Depreciation & amortization | $940,000 | $833,000 |
| Stock-based compensation | $5.11M | $7.01M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.